Form 8-K · Current report
Revvity 8-K, filed Nov 3, 2026
- Filed
- CIK
- 0000031791
- Accession no.
- 0000031791-26-000031
Summary
Revvity reported third-quarter 2026 revenue of $729 million and GAAP EPS from continuing operations of $0.56, with adjusted EPS of $1.38, and raised its full-year pro forma guidance. The company also disclosed pro forma financials for the probable sale of substantially all of its China Immunodiagnostics business for up to $200 million, and CEO Prahlad Singh said broad-based growth and strong execution drove results ahead of expectations.
Key points
- Revvity reported Q3 2026 revenue of $729 million, up from $699 million a year earlier; GAAP operating income from continuing operations was $95 million.
- Full-year 2026 pro forma guidance: total revenue of approximately $2.86 billion, pro forma organic revenue growth of approximately 5%, and pro forma adjusted EPS of $5.40-$5.45.
- Revvity signed a definitive agreement on July 31, 2026, to sell substantially all assets of its China Immunodiagnostics business for up to $200 million, with management believing the transaction is probable to close by the end of 2027.
- Revvity will host its 2026 Investor Day on November 13, 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition On November 3, 2026, Revvity, Inc. (the “Company”) announced its financial results for the third quarter ended October 4, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 of Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.